ClinicalTrials.gg

TargetBeta

SLC6A4

solute carrier family 6 member 4 · also 5-HTT, SERT1, HTT, OCD1 · Solute carrier family 6

4 programs in company-led studies act on SLC6A4, from 4 companies: 2 in phase 3, 2 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
VortioxetineruleH. Lundbeckphase 4621 runningHTR1A, HTR3A, SMSChEMBL
LevomilnacipranruleAbbViephase 4130 runningSLC6A2ChEMBL
lumateperoneruleJohnson & Johnsonphase 3256 runningDRD2, HTR2AChEMBL
TrazodoneruleAngelini Pharmaphase 3140 runningHTR2A, HTR2CChEMBL

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.